he recently published Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (1), is regarded as the primary source of information for psychiatric diagnostic criteria. Criticisms of the new edition have centered on the relative lack of scientific evidence for specific diagnostic classifications and unclear boundaries between true "illness" and the normal stresses of life. These concerns are valid and will always be part of the practice of medicine.
Diagnostic uncertainties are not specific to the field of psychiatry. For example, what causes fibromyalgia? Do current diagnostic criteria reliably represent patients who have this disorder? Why do people get idiopathic pulmonary fibrosis or multiple sclerosis? What is the best way to reliably assess the severity of chronic pain in persons who have it?
Diagnostic uncertainties help physicians better appreciate the "art of medicine." Physicians do not rely solely on objective data to determine a diagnosis and develop an effective treatment plan. If they did, 4 years of medical school and additional residency training would not have been necessary. The complexity of the human body and mind is such that physicians have grappled with ongoing clinical uncertainty for centuries. The more advanced our profession becomes, the more we clearly see what we do not really know.
The DSM-I and DSM-II were published in 1952 and 1968, respectively, and served mainly as glossaries of psychiatric diagnostic terminology (2, 3) . In 1980, the DSM-III was developed to improve psychiatric diagnostic reliability among clinicians (4, 5) . The DSM-IV, published in 1994, further advanced the field of psychiatry by depathologizing normal stressful experiences and including "significant impairment to overall function" as a qualifier to each psychiatric disorder (6) . Essentially, a patient cannot have a psychiatric disorder (and should not be treated for one) unless overall function is significantly impaired. This important distinction has not changed in the DSM-5.
The DSM-5 task force, appointed in 2006, used a multidisciplinary, collaborative, transparent, and evidencebased process to develop a diagnostic manual that was (when possible) focused on both the reliability and validity of psychiatric diagnostic criteria. The DSM-5 includes the following important improvements:
The number of psychiatric disorders decreased from 172 (DSM-IV) to 152 (DSM-5). (This does not include disorders that are "Not otherwise specified" or "Other specified/unspecified.") Many conditions were condensed into a more general and easier-to-use classification.
Hypochondriasis, pain disorder, somatization disorder, and undifferentiated somatoform disorder were condensed into somatic symptom disorder.
Substance abuse and dependence were replaced with a simpler diagnosis: substance use disorder.
Diagnostic criteria for schizoaffective disorder were clarified to include both longitudinal (not episodic) mood and psychotic symptoms.
Bereavement exclusion for major depressive disorder was dropped. Bereavement can manifest like any other psychosocial stressor and precipitate a discrete depressive episode. This diagnostic change supports psychiatric care for patients who have severe, disabling, and prolonged depression in the context of someone who has suffered a recent loss of a loved one. This diagnostic change also supports no psychiatric treatment for those who experience the expected, relatively shorter and less severe depressed mood that follows a similar loss.
A new diagnostic category, trauma-and stressorrelated disorders, was created to provide more emphasis on conditions that may occur when a patient either directly or indirectly experiences a traumatic event. Posttraumatic stress disorder now includes negative alterations with mood and cognitions, both of which are frequently encountered with patients who have had a traumatic event.
A new, more inclusive diagnostic category, neurocognitive disorders, replaced the DSM-IV category of dementia and amnestic disorders. The new category includes both major and mild forms of illness, with an emphasis on starting treatment sooner for early stages of neurocognitive impairment.
Cultural and gender diagnostic qualifiers, diagnostic markers (when available), and functional consequences to illness were included to help clinicians develop more targeted and individualized treatment plans.
The practice of medicine is an imperfect science, with the constant struggle of diagnostic and therapeutic uncertainty. This applies to the complex and dynamic field of psychiatry. Although recent advances help us to better understand, categorize, and treat psychiatric disorders (such as depression, bipolar disorder, anxiety, and substance misuse), there is more work to be done. It is easier to reliably diagnose and treat disorders when a specific cause is known. For example, most urinary tract infections can be quickly diagnosed and treated. Blood glucose levels can be reliably quantified. Most bone fractures can be accurately diagnosed by observing objective clinical features and radiologic findings. It is much more challenging to diagnose and treat disabling conditions that lack objective data, such as dysfunctional and maladaptive behavioral disorders.
The American Psychiatric Association has acknowledged these inherent limitations by creating a "living document" that will be revised as our evidence-based understanding of psychiatric disorders continues to evolve. It is also committed to ongoing changes in the DSM that will support the recovery of patients with mental illness. The DSM-5 represents the most up-to-date information for clinical diagnosis of mental disorders, and patients can be confident that it is the right resource for delivering the best care.
As a practicing internist-psychiatrist, I believe that the DSM-5 has consolidated and simplified many psychiatric conditions, while including important diagnostic qualifiers that address functional status and differences in culture and gender. These changes result in a more user-friendly DSM for primary care and mental health providers. It is certainly a work in progress, because evidence is still lacking in so many domains that affect both psychiatric diagnosis and treatment. This is the art of medicine.
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